154 related articles for article (PubMed ID: 37278655)
1. Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.
Palomino-Cabrera R; Tejerina F; Molero-Salinas A; Ferris M; Veintimilla C; Catalán P; Rodríguez Macias G; Alonso R; Muñoz P; García de Viedma D; Pérez-Lago L;
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0026623. PubMed ID: 37278655
[TBL] [Abstract][Full Text] [Related]
2. Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.
Gliga S; Lübke N; Killer A; Gruell H; Walker A; Dilthey AT; Thielen A; Lohr C; Flaßhove C; Krieg S; Pereira JV; Seraphin TP; Zaufel A; Däumer M; Orth HM; Feldt T; Bode JG; Klein F; Timm J; Luedde T; Jensen BO
Clin Infect Dis; 2023 Feb; 76(3):408-415. PubMed ID: 36189631
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.
Andrés C; González-Sánchez A; Jiménez M; Márquez-Algaba E; Piñana M; Fernández-Naval C; Esperalba J; Saubi N; Quer J; Rando-Segura A; Miarons M; Codina MG; Ruiz-Camps I; Pumarola T; Abrisqueta P; Antón A
Clin Microbiol Infect; 2023 Feb; 29(2):240-246. PubMed ID: 36067943
[TBL] [Abstract][Full Text] [Related]
4. Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study.
Woo MS; Brehm TT; Fischer M; Heyer A; Wichmann D; Jordan S; Nörz D; Lütgehetmann M; Addo MM; Lohse AW; Schmiedel S; Kluge S; Schulze Zur Wiesch J
Microbiol Spectr; 2023 Feb; 11(1):e0410322. PubMed ID: 36475890
[No Abstract] [Full Text] [Related]
5. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
Viruses; 2023 May; 15(6):. PubMed ID: 37376600
[TBL] [Abstract][Full Text] [Related]
6. Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.
Behzad A; Mohamed A; Ali A; Niinuma S; Butler AE; Alqahtani M
J Infect Public Health; 2024 Feb; 17(2):315-320. PubMed ID: 38160562
[TBL] [Abstract][Full Text] [Related]
7. Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events.
Yoshida J; Shiraishi K; Tanaka M
BMC Infect Dis; 2022 Dec; 22(1):902. PubMed ID: 36461006
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.
Drysdale M; Gibbons DC; Singh M; Rolland C; Lavoie L; Skingsley A; Lloyd EJ
Infection; 2024 Feb; 52(1):1-17. PubMed ID: 37776474
[TBL] [Abstract][Full Text] [Related]
9. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
[TBL] [Abstract][Full Text] [Related]
10. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G; Marcelin AG; Soulié C; Kaisaridi S; Lusivika-Nzinga C; Zafilaza K; Dorival C; Nailler L; Boston A; Ronchetti AM; Melenotte C; Cabié A; Choquet C; Trinh-Duc A; Lacombe K; Gaube G; Coustillères F; Pourcher V; Martellosio JP; Peiffer-Smadja N; Chauveau M; Housset P; Piroth L; Devaux M; Pialoux G; Martin A; Dubee V; Frey J; Le Bot A; Cazanave C; Petua P; Liblau R; Carrat F; Yordanov Y
Clin Microbiol Infect; 2023 Apr; 29(4):543.e5-543.e9. PubMed ID: 36586513
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
[TBL] [Abstract][Full Text] [Related]
12. Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
Driouich JS; Bernadin O; Touret F; de Lamballerie X; Nougairède A
Antiviral Res; 2023 Jul; 215():105638. PubMed ID: 37207822
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.
Cicchitto G; Cardillo L; Sequino D; Sabatini P; Adamo L; Marchitiello R; Viscardi M; Cozzolino L; Cavallera A; Bocchino M; Sanduzzi Zamparelli A; Ferrigno F; de Carlo E; de Martinis C; Fusco G
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680143
[TBL] [Abstract][Full Text] [Related]
14. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
Chesdachai S; Rivera CG; Cole KC; Teaford HR; Gonzalez Suarez ML; Larsen JJ; Ganesh R; Tulledge-Scheitel S; Razonable RR
Sci Rep; 2024 Mar; 14(1):5430. PubMed ID: 38443438
[TBL] [Abstract][Full Text] [Related]
15. Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.
Huygens S; Oude Munnink B; Gharbharan A; Koopmans M; Rijnders B
Clin Infect Dis; 2023 Feb; 76(3):e507-e509. PubMed ID: 35867699
[TBL] [Abstract][Full Text] [Related]
16. Wastewater Genomic Surveillance Captures Early Detection of Omicron in Utah.
Gupta P; Liao S; Ezekiel M; Novak N; Rossi A; LaCross N; Oakeson K; Rohrwasser A
Microbiol Spectr; 2023 Jun; 11(3):e0039123. PubMed ID: 37154725
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
18. Reply to "successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience": A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era.
Cassin R; Rampi N; C F; Muscatello A; Mariani B; Noto A; Rossi FG; Baldini L
Hematol Oncol; 2023 Feb; 41(1):213-217. PubMed ID: 36156809
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
20. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.
Focosi D; Casadevall A; Franchini M; Maggi F
Viruses; 2024 Jan; 16(2):. PubMed ID: 38399991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
